Consistent with these findings, combined PRNP silencing and GEM treatment significantly suppressed EMT progression in vitro, suggesting that PRNP serves as a critical regulator of pancreatic cancer aggressiveness through modulation of tumor-neural interactions. The gene discussed is PRNP; the disease is neoplasm.